Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2018 08:00 ET | Source: BioCanCell Ltd.

BioCanCell Announces Terms of $25 Million Funding Round

JERUSALEM, Jan. 23, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL) (the “Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 28, 2017 09:23 ET | Source: BioCanCell Ltd.

Shareholders Turn Down Tender Offer to Take BioCanCell Private

JERUSALEM, Dec. 28, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
December 11, 2017 16:01 ET | Source: BioCanCell Ltd.

Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round

JERUSALEM, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
November 15, 2017 16:01 ET | Source: BioCanCell Ltd.

BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer

JERUSALEM, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
October 30, 2017 07:00 ET | Source: BioCancell Ltd.

BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update

JERUSALEM, Oct. 30, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
August 14, 2017 07:00 ET | Source: BioCancell Ltd.

BioCanCell Announces Appointment of Ms. Ruti Alon to Board of Directors

JERUSALEM, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...